AZD1981   Click here for help

GtoPdb Ligand ID: 7680

Synonyms: AZD 1981 | AZD-1981
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD1981 was an investigational compound being assessed as a potential treatment for asthma. Mechanistically it is a potent, orally active, selective and reversible antagonist of the DP2 receptor (CRTH2).
This compound is now included for repurposing in the AstaZeneca's Open Innovation Pharmacology Toolbox. It was also Case Study (2) in the AZ 2014 review paper [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 96.63
Molecular weight 388.06
XLogP 4.12
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)Nc1cccc2c1c(Sc1ccc(cc1)Cl)c(n2CC(=O)O)C
Isomeric SMILES CC(=O)Nc1cccc2c1c(Sc1ccc(cc1)Cl)c(n2CC(=O)O)C
InChI InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)
InChI Key JWYIGNODXSRKGP-UHFFFAOYSA-N
Immunopharmacology Comments
AZD1981 acts as an antagonist of the GPCR, DP2 (a.k.a. CRTH2) expressed by Th2 lymphocytes and eosinophils. This mechanism would be expected to inhibit prostaglandin D2-driven chemotaxis.
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Phase 2 clinical candidate with predicted anti-asthmatic activity (see NCT00758589 for example). Has also completed Phase 2 clinical trials for COPD (NCT00690482) and chronic idiopathic urticaria (NCT02031679).